Cargando…
A Framework Proposal to Follow‐Up on Preclinical Convulsive Signals of a New Molecular Entity in First‐in‐Human Studies Using Electroencephalographic Monitoring
Traditionally, in dose‐escalating first‐in‐human (FiH) studies, a dose cap with a 10‐fold safety margin to the no observed effect level in animals is implemented if convulsive events are observed in animals. However, the convulsive risk seen in animals does not generally translate to humans. Several...
Autores principales: | Abt, Markus, Dinklo, Theo, Rothfuss, Andreas, Husar, Elisabeth, Dannecker, Robert, Kallivroussis, Katja, Peck, Richard, Doessegger, Lucette, Wandel, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851537/ https://www.ncbi.nlm.nih.gov/pubmed/30993670 http://dx.doi.org/10.1002/cpt.1455 |
Ejemplares similares
-
Clinical trial considerations on male contraception and collection of pregnancy information from female partners
por: Banholzer, Maria Longauer, et al.
Publicado: (2012) -
Electroencephalographic and behavioral convulsant effects of hydrobromide and hydrochloride salts of bupropion in conscious rodents
por: Henshall, David C, et al.
Publicado: (2009) -
Erratum to: Clinical trial considerations on male contraception and collection of pregnancy information from female partner: update
por: Banholzer, Maria Longauer, et al.
Publicado: (2016) -
Clinical trial considerations on male contraception and collection of pregnancy information from female partner: update
por: Banholzer, Maria Longauer, et al.
Publicado: (2016) -
Clinical development methodology for infusion-related reactions with monoclonal antibodies
por: Doessegger, Lucette, et al.
Publicado: (2015)